Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of
pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to
neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.